A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Clinical trial NCT01864746 · COMPLETED

Trial details

NCT number: NCT01864746
Sponsor: GBG Forschungs GmbH
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Cancer Hormonreceptor Positive Her2-normal Postneoadjuvant Treatment With CDK 4/6 Inhibitor CPS-EG Score

Start date: 2013-10-30
Primary completion: 2020-08-24
Enrollment: 1250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.